Cytomegalovirus seromismatching increases the risk of acute renal allograft rejection

被引:39
作者
McLaughlin, K
Wu, C
Fick, G
Muirhead, N
Hollomby, D
Jevnikar, A
机构
[1] London Hlth Sci Ctr, Div Nephrol, Dept Internal Med, London, ON, Canada
[2] Univ Western Ontario, London, ON, Canada
[3] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada
关键词
D O I
10.1097/00007890-200209270-00014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. There is an association between cytomegalovirus (CMV) infection or disease and acute allograft rejection in the setting of renal transplantation. There is, however, debate regarding the nature of this association, with evidence supporting both a "forward" relationship (CMV infection or disease precedes acute rejection) and a "backward" relationship- (CMV infection or disease follows acute rejection). The objective of this study was to determine whether. CMV matching had an independent effect on the risk of acute renal allograft rejection, which would support the view that CMV infection or disease is a risk factor for acute rejection. Methods. Retrospective single center study (using a prospectively maintained database) of 333, first cadaveric transplant recipients from January 1st 1991 to December 31st 1997. Primary end-point was incidence of acute rejection, diagnosed clinically or by renal biopsy, for different groups formed on the basis of CMV seromatching. Results. One hundred and ninety-four patients (58.3%) had at least one acute rejection episode. CMV seromismatched patients (donor +/recipient-) had a significantly higher rate of acute rejection than nonseromismatched patients (72.6% vs. 54.2%, P=0.005). Using multiple logistic regression, CMV seromis-match, delayed graft function, and biological induction were identified as independent predictors of acute rejection. The adjusted odds ratios for these were 2.28,.1.65, and 0.52, respectively. Conclusions. Patients who are CMV seromismatched are at higher risk of acute renal allograft rejection. This finding suggests that CMV infection or disease is a risk factor for acute rejection.
引用
收藏
页码:813 / 816
页数:4
相关论文
共 21 条
[1]   Human cytomegalovirus early infection, acute rejection, and major histocompatibility class II expression in transplanted lung - Molecular, immunocytochemical, and histopathologic investigations [J].
Arbustini, E ;
Morbini, P ;
Grasso, M ;
Diegoli, M ;
Fasani, R ;
Porcu, E ;
Banchieri, N ;
Perfetti, V ;
Pederzolli, C ;
Grossi, P ;
DallaGasperina, DD ;
Martinelli, L ;
Paulli, M ;
Ernst, M ;
Plachter, B ;
Vigano, M ;
Solcia, E .
TRANSPLANTATION, 1996, 61 (03) :418-427
[2]  
Bouedjoro-Camus MC, 1999, PRESSE MED, V28, P619
[3]   Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients [J].
Brennan, DC ;
Garlock, KA ;
Singer, GG ;
Schnitzler, MA ;
Lippmann, BJ ;
Buller, RS ;
Gaudreault-Keener, M ;
Lowell, JA ;
Shenoy, S ;
Howard, TK ;
Storch, GA .
TRANSPLANTATION, 1997, 64 (12) :1843-1846
[4]   Intercellular adhesion molecule-1 expression in endothelial cells is activated by cytomegalovirus immediate early proteins [J].
Burns, LJ ;
Pooley, JC ;
Walsh, DJ ;
Vercellotti, GM ;
Weber, ML ;
Kovacs, A .
TRANSPLANTATION, 1999, 67 (01) :137-144
[5]   Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment [J].
Craigen, JL ;
Grundy, JE .
TRANSPLANTATION, 1996, 62 (08) :1102-1108
[6]   THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RENAL-TRANSPLANTATION [J].
DAVIS, CL .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1990, 16 (03) :175-188
[7]   Cytomegalovirus infection and graft rejection in renal transplantation [J].
Dickenmann, MJ ;
Cathomas, G ;
Steiger, J ;
Mihatsch, MJ ;
Thiel, G ;
Tamm, M .
TRANSPLANTATION, 2001, 71 (06) :764-767
[8]   CHANGES OF ADHESION MOLECULE (LFA-1, ICAM-1) EXPRESSION ON MEMORY T-CELLS ACTIVATED WITH CYTOMEGALOVIRUS ANTIGEN [J].
ITO, M ;
WATANABE, M ;
KAMIYA, H ;
SAKURAI, M .
CELLULAR IMMUNOLOGY, 1995, 160 (01) :8-13
[9]   Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation [J].
Lowance, D ;
Neumayer, HH ;
Legendre, CM ;
Squifflet, JP ;
Kovarik, J ;
Brennan, PJ ;
Norman, D ;
Mendez, R ;
Keating, MR ;
Coggon, GL ;
Crisp, A ;
Lee, IC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (19) :1462-1470
[10]   Idiopathic thrombocytopenia after cytomegalovirus infection in a renal transplant recipient [J].
McLaughiin, K ;
Cruickshank, M ;
Hollomby, D ;
Jevnikar, A ;
Muirhead, N .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (06)